After BCG therapy, BC recurrence was associated with elevated levels of specific proteins (ANG, APOE, A1AT, CA9, MMP9, MMP10, PAI1, SDC1, VEGFA) in the OncuriaTM panel, demonstrating its potential for assessing the effectiveness of intravesical BCG treatment and predicting relapse risk in BC patients [22]. The gene discussed is SERPINE1; the disease is breast cancer.